Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of
the Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): January 9, 2020
AZURRX BIOPHARMA, INC.
(Exact name of
Registrant as specified in its Charter)
|
Delaware
|
001-37853
|
46-4993860
|
|
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
760
Parkside Avenue
Downstate
Biotechnology Incubator,
Suite
304
Brooklyn, New York
|
|
11226
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:(646) 699-7855
(Name, address,
including zip code, and telephone number, including area code, of
agent for service of process)
NOT APPLICABLE
(Former Name or
Former Address, if Changes Since Last Report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par
value $0.0001 per share
|
AZRX
|
Nasdaq Capital
Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
240.12b-2) ☒
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act ☐
Item
8.01. Other Events.
On January 9,
2020, AzurRx BioPharma, Inc. (the “Company”) issued a press
release announcing that it will present new data from five
patients enrolled in its Phase 2 study for its lead development
candidate MS1819-SD at the 2020 Biotech Showcase Conference being
held at the Hilton San Francisco Union Square Hotel (Yosemite C -
Ballroom Level) on Monday, January 13th at 3:00 p.m.
Pacific Time. A copy of the press
release is attached hereto as Exhibit 99.1.
This Current Report
on Form 8-K and the exhibit attached hereto may contain, among
other things, certain forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, including,
without limitation, (i) statements with respect to the Company's
plans, objectives, expectations and intentions; and (ii) other
statements identified by words such as "may", "could", "would",
"should", "believes", "expects", "anticipates", "estimates",
"intends", "plans" or similar expressions. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and
uncertainties.
Item 9.01. Financial Statements and
Exhibits.
(d)
Exhibits
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
Press Release
issued by AzurRx BioPharma, Inc., dated January 9,
2020
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AzurRx BioPharma, Inc.
|
|
|
|
|
|
|
|
|
Date: January 10,
2020
|
By:
|
/s/ James
Sapirstein
|
|
|
|
|
Name: James Sapirstein
|
|
|
|
|
Title: President and Chief Executive Officer
|
|
|
|